DFTX insider filings
Definium Therapeutics, Inc. — 43 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-29. Screen DFTX transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 18 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings by 5 insiders — 81,951 shares, $3,023,010 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 31,550 shares @ $36.57 ($1,153,784) by Barrow Robert, filed 2026-09-29.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Barrow Robert — Chief Executive Officer, Director | 4 | — | 2 legs · 50,573 sh · $1,875,516 | 3 |
| Sullivan Mark — Chief Legal Officer | 3 | — | 1 leg · 14,051 sh · $513,845 | 2 |
| Karlin Daniel — Chief Medical Officer, Director | 3 | — | 1 leg · 10,853 sh · $396,894 | 2 |
| Roberts Brandi — Chief Financial Officer | 3 | — | 1 leg · 3,377 sh · $123,497 | 2 |
| Wiley Matthew T. — Chief Commercial Officer | 3 | — | 1 leg · 3,097 sh · $113,257 | 2 |
| Krebs Andreas — Director | 1 | — | — | 2 |
| Vallone Carol A — Director | 1 | — | — | 2 |
Recent insider filings — Definium Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-29 | 4 | Karlin Daniel — Chief Medical Officer, Director | Sale (S): 10,853 @ $36.57 | EDGAR |
| 2026-09-29 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 31,550 @ $36.57 | EDGAR |
| 2026-09-29 | 4 | Wiley Matthew T. — Chief Commercial Officer | Sale (S): 3,097 @ $36.57 | EDGAR |
| 2026-09-29 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 14,051 @ $36.57 | EDGAR |
| 2026-09-29 | 4 | Roberts Brandi — Chief Financial Officer | Sale (S): 3,377 @ $36.57 | EDGAR |
| 2026-09-18 | 4 | Krebs Andreas — Director | Option exercise (M): 1,629 @ $35.52 · Option exercise (M): 1,629 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Vallone Carol A — Director | Option exercise (M): 1,086 @ $35.52 · Option exercise (M): 1,086 (derivative) @ $0 | EDGAR |
| 2026-09-14 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 750,000 @ $0 | EDGAR |
| 2026-09-14 | 4 | Roberts Brandi — Chief Financial Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2026-09-14 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2026-09-14 | 4 | Wiley Matthew T. — Chief Commercial Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2026-09-14 | 4 | Karlin Daniel — Chief Medical Officer | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2026-09-04 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 40,000 @ $0 · Sale (S): 19,023 @ $37.94 | EDGAR |
| 2026-08-12 | 4 | Roberts Brandi — Chief Financial Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-08-12 | 4 | Wiley Matthew T. — Chief Commercial Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-08-12 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-08-12 | 4 | Karlin Daniel — Chief Medical Officer | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-08-12 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 375,000 @ $0 | EDGAR |
| 2026-06-26 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 10,035 @ $45.03 | EDGAR |
| 2026-06-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 29,208 @ $45.03 | EDGAR |
| 2026-06-26 | 4 | Wiley Matthew T. — Chief Commercial Officer | Sale (S): 2,867 @ $45.03 | EDGAR |
| 2026-06-26 | 4 | Roberts Brandi — Chief Financial Officer | Sale (S): 3,013 @ $45.03 | EDGAR |
| 2026-06-26 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 13,008 @ $45.03 | EDGAR |
| 2026-06-22 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 375,000 @ $0 | EDGAR |
| 2026-06-22 | 4 | Karlin Daniel — Chief Medical Officer | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2026-06-22 | 4 | Wiley Matthew T. — Chief Commercial Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-06-22 | 4 | Roberts Brandi — Chief Financial Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-06-22 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 62,500 @ $0 | EDGAR |
| 2026-06-15 | 4 | Adsett Roger — Director | Grant/award (A): 3,555 @ $0 · Grant/award (A): 14,620 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | CRYSTAL ROGER — Director | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Krebs Andreas — Director | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Vallone Carol A — Director | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | GRYSKA DAVID W — Director | Grant/award (A): 4,666 @ $0 · Grant/award (A): 19,188 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Karlin Daniel — Chief Medical Officer | Sale (S): 8,018 @ $18.47 | EDGAR |
| 2026-03-26 | 4 | Barrow Robert — Chief Executive Officer, Director | Sale (S): 24,431 @ $18.47 | EDGAR |
| 2026-03-26 | 4 | Sullivan Mark — Chief Legal Officer | Sale (S): 10,702 @ $18.47 | EDGAR |
| 2026-02-05 | 4 | Karlin Daniel — Chief Medical Officer | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-02-05 | 4 | Barrow Robert — Chief Executive Officer, Director | Grant/award (A): 320,000 @ $0 | EDGAR |
| 2026-02-05 | 4 | Wiley Matthew T. — Chief Commercial Officer | Grant/award (A): 115,000 @ $0 | EDGAR |
| 2026-02-05 | 4 | Roberts Brandi — Chief Financial Officer | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2026-02-05 | 4 | Sullivan Mark — Chief Legal Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2026-01-29 | 4 | Adsett Roger — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Definium Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DFTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →